<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Insulin aspart (including biosimilars available in Canada): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Insulin aspart (including biosimilars available in Canada): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Insulin aspart (including biosimilars available in Canada): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11768" href="/d/html/11768.html" rel="external">see "Insulin aspart (including biosimilars available in Canada): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13379" href="/d/html/13379.html" rel="external">see "Insulin aspart (including biosimilars available in Canada): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F2104823"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Fiasp;</li>
<li>Fiasp FlexTouch;</li>
<li>Fiasp PenFill;</li>
<li>Fiasp PumpCart;</li>
<li>NovoLOG;</li>
<li>NovoLOG FlexPen;</li>
<li>NovoLOG FlexPen ReliOn;</li>
<li>NovoLOG PenFill;</li>
<li>NovoLOG ReliOn</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868737"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Fiasp;</li>
<li>Kirsty;</li>
<li>NovoRapid;</li>
<li>Trurapi;</li>
<li>Trurapi Solostar</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F2104827"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Insulin, Rapid-Acting</li></ul></div>
<div class="block doa drugH1Div" id="F2104863"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Insulin aspart is a rapid-acting insulin analog available in a conventional formulation (eg, NovoLOG, NovoRapid [Canadian product]) and a faster-acting formulation (Fiasp), which differ in onset of action and administration instructions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28205039','lexi-content-ref-29316130']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28205039','lexi-content-ref-29316130'])">Ref</a></span>). These products are not interchangeable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ISMP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ISMP.1'])">Ref</a></span>). In Canada, Kirsty and Trurapi are approved as biosimilars to NovoRapid. Insulin requirements vary between patients; monitor glucose levels frequently and individualize dose.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dc2823b3-202c-4a44-a2d1-58b5084839e6">Diabetes mellitus, type 1, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 1, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Insulin aspart must be used concomitantly with intermediate- or long-acting insulin (ie, multiple daily injection regimen) or in a continuous subcutaneous insulin infusion device. <b>The total daily doses (TDD) presented below are expressed as the</b>
<b>total units/kg/day of all insulin formulations combined.</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>General insulin dosing:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Initial TDD:</i></b>
<b>SUBQ:</b> ~0.4 to 0.5 units/kg/day; conservative initial doses of 0.2 to 0.4 units/kg/day may be considered to avoid the potential for hypoglycemia; higher initial doses may be required in patients with obesity, or who are sedentary or presenting with ketoacidosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25869408','lexi-content-ref-ADA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25869408','lexi-content-ref-ADA.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Usual TDD maintenance range:</i></b>
<b>SUBQ: </b>0.4 to 1 units/kg/day in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Division of TDD (multiple daily injections):</i></b></p>
<p style="text-indent:-2em;margin-left:8em;">Basal insulin: Generally, 40% to 50% of the TDD is given as basal insulin (intermediate- or long-acting) in 1 to 2 daily injections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25869408','lexi-content-ref-ADA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25869408','lexi-content-ref-ADA.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Prandial insulin: The remaining portion (ie, 50% to 60%) of the TDD is then divided and administered before, at, or just after mealtimes depending on the formulation (eg, short-, rapid-, ultra-rapid acting) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25869408','lexi-content-ref-ADA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25869408','lexi-content-ref-ADA.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Dosage adjustment:</b> Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Adjust dose to maintain premeal and bedtime glucose in target range. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2ad35dab-7cea-4ec1-88c5-ab393b3cfc22">Diabetes mellitus, type 2, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 2, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May be used if glycemic targets are not met despite adequately titrated basal insulin (eg, fasting glucose levels not at goal, basal insulin dose &gt;0.5 units/kg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021'])">Ref</a></span>). For regimens containing basal and prandial insulin, consider discontinuing noninsulin agents other than metformin, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter-2 inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-30291106']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-30291106'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Prandial insulin regimens are typically initiated as 1 daily injection administered before the largest meal; additional mealtime injections may be added based on results of glucose monitoring. In patients with HbA<sub>1c</sub> &lt;8% when prandial insulin is initiated, consider reducing the basal insulin daily dose by 4 units/day <b>or</b> by 10% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>SUBQ: </b>4 to 6 units <b>or</b> 10% of the <b>basal</b> insulin dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32022600','lexi-content-ref-ADA.2021','lexi-content-ref-Wexler.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32022600','lexi-content-ref-ADA.2021','lexi-content-ref-Wexler.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Dosage adjustment: </i>Note: </b>Individualize dosage adjustments based on patient-specific factors (eg, glucose levels, carbohydrate intake) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>For persistently elevated glucose levels: SUBQ: </b>Consider intensification of dietary modifications and/or increasing the corresponding mealtime dose(s) by 1 to 2 units <b>or</b> by 10% to 15% every 3 days to achieve glycemic targets while avoiding hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-Wexler.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-Wexler.1'])">Ref</a></span>). <b>Note:</b> More aggressive dose increases (eg, by ≥5 units) may be required in patients already taking &gt;20 units/dose of insulin aspart (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wexler.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wexler.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>For hypoglycemia: SUBQ: </b>For unexplained mild to moderate hypoglycemia, consider decreasing the corresponding mealtime dose(s) by 10% to 20% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021'])">Ref</a></span>); for hypoglycemia requiring assistance from another person or blood glucose &lt;40 mg/dL, consider decreasing the corresponding mealtime dose(s) by 20% to 50% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32022600','lexi-content-ref-Wexler.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32022600','lexi-content-ref-Wexler.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="87b665ef-68eb-453a-80ad-91aa786100ef">Patients with diabetes receiving enteral feedings</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Patients with diabetes receiving enteral feedings:</b>
<b> Note:</b> TDD of insulin is divided into a basal component (intermediate- or long-acting insulin) and nutritional and correctional components (regular insulin or rapid-acting insulins).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nutritional:</i>
<b>SUBQ:</b> 1 unit of insulin aspart per 10 to 15 g of carbohydrate prior to each bolus feeding; in patients receiving continuous feeds, administer every 4 hours based on the amount of carbohydrate administered over each 4-hour period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-22223765']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-22223765'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Correctional: </i>
<b>SUBQ:</b> Administer correctional insulin as needed prior to each feeding (for bolus feeds) or every 4 hours (for continuous feeds) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021'])">Ref</a></span>). Dosing is individualized; one example of an empiric correctional dose is 1 to 2 units per 40 to 50 mg/dL above target glucose level; patients with known insulin resistance or who are receiving glucocorticoids may require higher correctional doses (eg, 4 units per 50 mg/dL above target glucose level) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14747243','lexi-content-ref-22223765','lexi-content-ref-32931166','lexi-content-ref-Inzucchi.1','lexi-content-ref-29162977']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14747243','lexi-content-ref-22223765','lexi-content-ref-32931166','lexi-content-ref-Inzucchi.1','lexi-content-ref-29162977'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="416ede05-90f0-450c-a473-d7b0ea1dad5e">Patients with diabetes undergoing surgery and using an insulin pump</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Patients with diabetes undergoing surgery and using an insulin pump: SUBQ:</b> For short procedures (eg, &lt;2 hours), continue the usual pump "basal" insulin infusion rate, with or without a temporary 20% to 40% rate reduction, on the morning of the procedure. For long and complex procedures, consider transitioning from the insulin pump to an IV regular insulin infusion perioperatively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-29162977']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-29162977'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="227d5854-46f0-42a3-acb6-6009a78c892a">Diabetic ketoacidosis, mild to moderate, uncomplicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetic ketoacidosis, mild to moderate, uncomplicated (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> SUBQ insulin aspart may be used as an alternative to IV regular insulin in patients in whom management of diabetic ketoacidosis (DKA) outside of a critical care area is appropriate; faster-acting insulin aspart products (eg, Fiasp) have not been evaluated for this purpose. IV regular insulin (preferred over IV rapid-acting insulin analogs) should be used in patients with severe DKA, evidence of hyperosmolar hyperglycemic state (eg, altered mental status), persistent hypotension, or other critical illness, as well as during pregnancy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28183452','lexi-content-ref-19564476','lexi-content-ref-15277410']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28183452','lexi-content-ref-19564476','lexi-content-ref-15277410'])">Ref</a></span>). Begin correction of fluid deficits, if present. If serum potassium is &lt;3.3 mEq/L on initial presentation, delay insulin administration until serum potassium reaches ≥3.3 mEq/L. Address other electrolyte abnormalities, as needed, during insulin administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19564476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19564476'])">Ref</a></span>). In patients with initial serum glucose &lt;250 mg/dL, initiate dextrose-containing IV fluids at the time of insulin initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28924481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28924481'])">Ref</a></span>). An example of a dosing regimen is as follows; refer to institutional protocols:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>1-hour interval dosing:</i>
<b>SUBQ:</b> Initial: 0.3 units/kg, followed by 0.1 units/kg every hour until blood glucose &lt;250 mg/dL, then decrease to 0.05 units/kg every hour until resolution of ketoacidosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15277410']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15277410'])">Ref</a></span>). May increase dose (eg, by double) if serum glucose does not decrease by ~50 to 75 mg/dL in the first hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.1','lexi-content-ref-19564476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.1','lexi-content-ref-19564476'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>2-hour interval dosing:</i>
<b>SUBQ:</b> Initial: 0.3 units/kg, followed by 0.2 units/kg 1 hour later and then every 2 hours thereafter until blood glucose &lt;250 mg/dL, then decrease to 0.1 units/kg every 2 hours until resolution of ketoacidosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15277410']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15277410'])">Ref</a></span>). May increase dose (eg, by double) if serum glucose does not decrease by ~50 to 75 mg/dL in the first hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.1','lexi-content-ref-19564476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.1','lexi-content-ref-19564476'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="70b35ef8-5589-4fcf-8fcb-ab71c5c307ec">Hyperglycemia, hospitalized patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperglycemia, hospitalized patients (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use in patients with persistent hyperglycemia (eg, blood glucose ≥140 to 180 mg/dL for &gt;12 to 24 hours) with or without a history of diabetes; use of institution-specific protocols to achieve glycemic targets and minimize hypoglycemia is encouraged (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-22223765','lexi-content-ref-23164767']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-22223765','lexi-content-ref-23164767'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Correctional insulin:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>For use in addition to scheduled basal and nutritional insulin to achieve glycemic targets; prolonged use of correctional insulin without basal insulin is discouraged (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-19454396']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-19454396'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>SUBQ:</b> Refer to institution-specific protocols; one example of an empiric correctional dose is 1 to 2 units per 40 to 50 mg/dL above target glucose level; dose is typically administered with meals (or bolus feeds) or every 4 hours (if NPO or receiving continuous feeds); patients with known insulin resistance or who are receiving glucocorticoids may require higher correctional doses (eg, 4 units per 50 mg/dL above target glucose level) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-14747243','lexi-content-ref-22223765','lexi-content-ref-32931166','lexi-content-ref-Inzucchi.1','lexi-content-ref-29162977']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-14747243','lexi-content-ref-22223765','lexi-content-ref-32931166','lexi-content-ref-Inzucchi.1','lexi-content-ref-29162977'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Nutritional insulin:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial daily dosage:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Patients not receiving nutritional insulin prior to hospitalization:</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>
<i>Patients eating meals:</i></b></p>
<p style="text-indent:-2em;margin-left:12em;">
<b>SUBQ:</b> 0.03 to 0.1 units/kg/<b>meal </b>administered with or just after meals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-22223765']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-22223765'])">Ref</a></span>). <b>Note: </b>Dose is individualized; consider doses at the lower end of this range in older patients and in those with renal impairment; consider doses at the higher end of this range in patients receiving glucocorticoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22223765']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22223765'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>
<i>Patients receiving enteral feeds:</i></b></p>
<p style="text-indent:-2em;margin-left:12em;">
<b>SUBQ:</b> 1 unit of insulin aspart per 10 to 15 g of carbohydrate prior to each bolus feeding; in patients receiving continuous feeds, administer every 4 hours based on the amount of carbohydrate administered over each 4-hour period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-22223765']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-22223765'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Patients receiving nutritional insulin prior to hospitalization:</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>SUBQ:</b> Continue the prehospitalization nutritional insulin dose; an empiric 25% to 50% dose reduction may be considered in patients with impaired renal function, poor nutritional intake, or admission glucose levels &lt;100 mg/dL; higher doses may be required in patients receiving glucocorticoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2021','lexi-content-ref-22223765','lexi-content-ref-Inzucchi.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2021','lexi-content-ref-22223765','lexi-content-ref-Inzucchi.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Dosage adjustment:</i> Adjust daily dose by 10% to 20% every 2 to 3 days to achieve glycemic targets. Consider reducing dosage for glucose levels &lt;100 mg/dL to avoid hypoglycemia; in patients with glucose levels &lt;40 mg/dL, larger dose reductions (eg, by 20% to 40%) may be needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32022600','lexi-content-ref-19454396']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32022600','lexi-content-ref-19454396'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991225"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustments may be needed. Renal impairment may change insulin requirements; monitor blood glucose closely.</p></div>
<div class="block doha drugH1Div" id="F50988447"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustments may be needed. Hepatic impairment may change insulin requirements; monitor blood glucose closely.</p></div>
<div class="block doe drugH1Div" id="F2307924"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing; avoid insulin regimens that only use short- or rapid-acting insulins dosed based on current blood glucose levels in the absence of basal or long-acting insulin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>).</p></div>
<div class="block dop drugH1Div" id="F2104862"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13379" href="/d/html/13379.html" rel="external">see "Insulin aspart (including biosimilars available in Canada): Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">Insulin aspart is a rapid-acting insulin analog available in a conventional formulation (eg, NovoLog, NovoRapid [Canadian product]) and a faster-acting formulation (Fiasp), which differ in onset of action and administration instructions and risk of hypoglycemic episodes. These products are not interchangeable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ISMP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ISMP.1'])">Ref</a></span>).</p>
<p style="text-indent:0em;margin-top:2em;">Insulin doses should be individualized based on patient needs; adjustments may be necessary with changes in physical activity, meal patterns, acute illness, or with changes in renal or hepatic function. Insulin requirements vary dramatically between patients and dictates frequent monitoring and close medical supervision. Insulin regimens vary widely by region, practice, and institution; consult institution-specific guidelines.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d5956846-9e6c-4def-954b-a126316b2bbe">Diabetes mellitus, type 1</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 1:</b> Infants, Children, and Adolescents: <b>Note:</b> Insulin aspart must be used concomitantly with intermediate- or long-acting insulin (ie, multiple daily injection regimen) or in a continuous subcutaneous infusion pump. The daily doses presented are expressed as the <b>total units/kg/day of all insulin formulations combined</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>General insulin dosing: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial total daily insulin: </i>SubQ: Initial: 0.4 to 0.5 units/kg/day in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25869408','lexi-content-ref-ADA.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25869408','lexi-content-ref-ADA.2020'])">Ref</a></span>); usual range: 0.4 to 1 units/kg/day in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25869408','lexi-content-ref-ADA.2020','lexi-content-ref-15616254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25869408','lexi-content-ref-ADA.2020','lexi-content-ref-15616254'])">Ref</a></span>); lower doses (0.25 units/kg/day) may be used, especially in young children, to avoid potential hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26472948']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26472948'])">Ref</a></span>); higher doses may be necessary for some patients (eg, obese, concomitant steroids, puberty, sedentary lifestyle, following diabetic ketoacidosis presentation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25869408','lexi-content-ref-ADA.2020','lexi-content-ref-15616254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25869408','lexi-content-ref-ADA.2020','lexi-content-ref-15616254'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Usual total daily maintenance range:</i> SubQ: Doses must be individualized; however, an estimate can be determined based on phase of diabetes and level of maturity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29999222','lexi-content-ref-28726299']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29999222','lexi-content-ref-28726299'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Partial remission phase (Honeymoon phase): &lt;0.5 units/kg/day.</p>
<p style="text-indent:-2em;margin-left:8em;">Prepubertal children (not in partial remission):</p>
<p style="text-indent:-2em;margin-left:10em;">Infants ≥6 months and Children ≤6 years: 0.4 to 0.8 units/kg/day.</p>
<p style="text-indent:-2em;margin-left:10em;">Children ≥7 years: 0.7 to 1 units/kg/day.</p>
<p style="text-indent:-2em;margin-left:10em;">Pubescent Children and Adolescents: During puberty, requirements may substantially increase to &gt;1 unit/kg/day and in some cases up to 2 units/kg/day.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Division of daily insulin requirement (multiple daily injections): </i></p>
<p style="text-indent:-2em;margin-left:8em;">Basal insulin: Generally, ~30% to 50% of the total daily insulin is given as basal insulin (intermediate- or long-acting) in 1 to 2 daily injections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25869408','lexi-content-ref-ADA.2020','lexi-content-ref-29999222','lexi-content-ref-Peters.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25869408','lexi-content-ref-ADA.2020','lexi-content-ref-29999222','lexi-content-ref-Peters.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Prandial insulin: The remaining portion of the total daily dose is then divided and administered before or at mealtimes (depending on the formulation) as a rapid-acting (eg, aspart, glulisine, lispro) or short-acting (regular). In most type 1 patients, the use of a rapid-acting insulin analog is preferred over regular insulin to reduce hypoglycemia risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25869408','lexi-content-ref-ADA.2020','lexi-content-ref-24935775','lexi-content-ref-29999222']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25869408','lexi-content-ref-ADA.2020','lexi-content-ref-24935775','lexi-content-ref-29999222'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage titration:</b> Treatment and monitoring regimens must be individualized to maintain premeal and bedtime glucose in target range; titrate dose to achieve glucose control and avoid hypoglycemia. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4c0530af-c6d3-4cf5-a815-8e4e90cb9338">Diabetic ketoacidosis, uncomplicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetic ketoacidosis, uncomplicated: </b>Limited data available: Infants, Children, and Adolescents: SubQ: 0.15 units/kg/dose every 2 to 3 hours until resolution of metabolic acidosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29900641','lexi-content-ref-29797212','lexi-content-ref-20550713']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29900641','lexi-content-ref-29797212','lexi-content-ref-20550713'])">Ref</a></span>); if serum glucose decreases by &gt;100 mg/dL/hour, reduce dose to 0.1 units/kg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20550713']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20550713'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51114005"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; insulin requirements are reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.</p></div>
<div class="block dohp drugH1Div" id="F51114006"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.</p></div>
<div class="block adr drugH1Div" id="F2104840"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Rates of adverse reactions were defined during combination therapy with other insulins (NPH, detemir, or glargine). Adverse reactions are reported for adults, unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Severe hypoglycemia (adults, children, and adolescents: Type 1: 1% to 17%, Type 2: 3% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (adults: 3% to 28%; children and adolescents: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (adults: 5% to 12%; children and adolescents: 6% to 10%), hyporeflexia (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (20% to 24%), viral respiratory tract infection (children and adolescents: 21% to 23%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Accidental injury (11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Onychomycosis (10%), dermatological disorder (5%), allergic skin rash (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Vomiting (children and adolescents: 3% to 8%), nausea (5% to 7%), abdominal pain (5%), diarrhea (3% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (6% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (children and adolescents: 6% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Infusion site reaction (10%), injection site reaction (children and adolescents: 4%; adults: 2%), lipoatrophy at injection site (children and adolescents: 2%; adults: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal sensory symptoms (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (4% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (children and adolescents: 8% to 12%; adults: 7% to 9%), rhinitis (children and adolescents: 4% to 6%), sinusitis (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (children and adolescents: 6% to 8%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Facial edema, peripheral edema</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Diabetic retinopathy, weight gain</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Erythema at injection site, injection site pruritus, swelling at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Peripheral neuropathy</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Error of refraction</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Amyloidosis (localized cutaneous at injection site), anaphylaxis</p></div>
<div class="block coi drugH1Div" id="F2104835"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to insulin aspart or any component of the formulation; during episodes of hypoglycemia </p></div>
<div class="block war drugH1Div" id="F2104836"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Glycemic control: Hyper- or hypoglycemia may result from changes in insulin strength, manufacturer, type, and/or administration method. The most common adverse effect of insulin is hypoglycemia. The timing of hypoglycemia differs among various insulin formulations. Hypoglycemia may result from changes in meal pattern (eg, macronutrient content, timing of meals), changes in the level of physical activity, increased work or exercise without eating, or changes to coadministered medications. Use of long-acting insulin preparations (eg, insulin degludec, insulin detemir, insulin glargine) may delay recovery from hypoglycemia. Patients with renal or hepatic impairment may be at a higher risk. Symptoms differ in patients and may change over time in the same patient; awareness may be less pronounced in those with long-standing diabetes, diabetic nerve disease, patients taking beta-blockers, or in those who experience recurrent hypoglycemia. Profound and prolonged episodes of hypoglycemia may result in convulsions, unconsciousness, temporary or permanent brain damage, or even death. Insulin requirements may be altered during illness, emotional disturbances, or other stressors. Instruct patients to use caution with ethanol; may increase risk of hypoglycemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions (serious, life-threatening and anaphylaxis) have occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypokalemia: Insulin (especially IV insulin) causes a shift of potassium from the extracellular space to the intracellular space, possibly producing hypokalemia. If left untreated, hypokalemia may result in respiratory paralysis, ventricular arrhythmia and even death. Use with caution in patients at risk for hypokalemia (eg, loop diuretic use).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery:</p>
<p style="text-indent:-2em;margin-left:6em;">– Type 2 diabetes, hypoglycemia: Closely monitor insulin dose requirement throughout active weight loss with a goal of eliminating antidiabetic therapy or transitioning to agents without hypoglycemic potential; hypoglycemia after gastric bypass, sleeve gastrectomy, and gastric band may occur (Mechanick 2020). Insulin secretion and sensitivity may be partially or completely restored after these procedures (Korner 2009; Peterli 2012). Rates and timing of type 2 diabetes improvement and resolution vary widely by patient. Insulin dose reduction of ≥75% has been suggested after gastric bypass for patients without severe β-cell failure (fasting c-peptide &lt;0.3 nmol/L) (Cruijsen 2014). Avoid the use of bolus insulin injections or dose conservatively with close clinical monitoring in the early phases after surgery.</p>
<p style="text-indent:-2em;margin-left:6em;">– Weight gain: Insulin therapy is preferred if antidiabetic therapy is required during the perioperative period (Mechanick 2019). Evaluate risk versus benefit of long-term postoperative use and consider alternative therapy due to potential for insulin-induced weight gain (Apovian 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac disease: Concurrent use with peroxisome proliferator-activated receptor (PPAR)-gamma agonists, including thiazolidinediones, may cause dose-related fluid retention and lead to or exacerbate heart failure, particularly when used in combination with insulin. If PPAR-gamma agonists are prescribed, monitor for signs and symptoms of heart failure. If heart failure develops, consider PPAR-gamma agonist dosage reduction or therapy discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment. Risk of hypoglycemia may be increased; more frequent monitoring and dosage adjustments may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment. Risk of hypoglycemia may be increased; more frequent monitoring and dosage adjustments may be required.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hospitalized patients: Prolonged use of a sliding scale insulin regimen in the inpatient setting is strongly discouraged. In the critical care setting, continuous IV insulin infusion (insulin regular) has been shown to best achieve glycemic targets. In noncritically ill patients with either poor oral intake or taking nothing by mouth, basal insulin use is preferred, with correctional doses (insulin regular or rapid-acting insulin) as needed. In noncritically ill patients with adequate nutritional intake, a combination of basal insulin along with nutritional and correctional components (insulin regular or rapid-acting insulin) is preferred. An effective insulin regimen will achieve the goal glucose range without the risk of severe hypoglycemia. A blood glucose value &lt;70 mg/dL should prompt a treatment regimen review and change, if necessary, to prevent further hypoglycemia (ADA 2023).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Fiasp: Use FlexTouch pens and PenFill cartridges with caution in patients with visual impairment who rely on audible clicks to dial dose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Multiple dose injection pens: According to the Centers for Disease Control and Prevention (CDC), pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of the risk of infection. The injection device should be clearly labeled with individual patient information to ensure that the correct pen is used (CDC 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">• Prefilled pen devices: Do not transfer insulin aspart from a prefilled pen to a syringe.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Continuous subcutaneous insulin infusion administration: Insulin aspart may be administered via continuous subcutaneous insulin infusion; do not dilute or mix with other insulin formulations. Rule out external pump failure if unexplained hyperglycemia or ketosis occurs; temporary SUBQ insulin administration may be required until the problem is identified and corrected.</p>
<p style="text-indent:-2em;margin-left:4em;">• IV administration: Insulin aspart may be administered IV in selected clinical situations to control hyperglycemia; close medical supervision is required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Patient education: Diabetes self-management education is essential to maximize the effectiveness of therapy.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F54331405"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Insulin aspart is available in a conventional formulation (NovoLog) and a faster-acting formulation (Fiasp), which differ in onset of action and administration instructions. Pediatric patients with type 1 diabetes treated with mealtime and postmeal Fiasp experience a higher incidence of hypoglycemia compared to patients treated with NovoLog, with the greatest incidence occurring overnight. Monitor glucose levels closely.</p></div>
<div class="block foc drugH1Div" id="F2104880"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fiasp: 100 units/mL (10 mL) [contains metacresol, phenol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NovoLOG: 100 units/mL (10 mL) [contains metacresol, phenol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NovoLOG ReliOn: 100 units/mL (10 mL) [contains metacresol, phenol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 units/mL (10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Cartridge, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fiasp PenFill: 100 units/mL (3 mL) [contains metacresol, phenol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fiasp PumpCart: 100 units/mL (1.6 mL) [contains metacresol, phenol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NovoLOG PenFill: 100 units/mL (3 mL) [contains metacresol, phenol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 units/mL (3 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Pen-injector, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fiasp FlexTouch: 100 units/mL (3 mL) [contains metacresol, phenol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NovoLOG FlexPen: 100 units/mL (3 mL) [contains metacresol, phenol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NovoLOG FlexPen ReliOn: 100 units/mL (3 mL) [contains metacresol, phenol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 units/mL (3 mL)</p></div>
<div class="block geq drugH1Div" id="F2142861"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F3422170"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Fiasp Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $34.72</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Insulin Aspart Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $8.68</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (NovoLOG Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $8.68</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (NovoLOG ReliOn Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $8.68</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Cartridge</b> (Fiasp PenFill Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $43.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Cartridge</b> (Fiasp PumpCart Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $43.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Cartridge</b> (NovoLOG PenFill Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $10.75</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Pen-injector</b> (Fiasp FlexTouch Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $44.71</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Pen-injector</b> (NovoLOG FlexPen ReliOn Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $11.18</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Pen-injector</b> (NovoLOG FlexPen Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 units/mL (per mL): $11.18</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868738"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fiasp: 100 units/mL (10 mL) [contains metacresol, phenol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Kirsty: 100 units/mL (10 mL) [contains metacresol, phenol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NovoRapid: 100 units/mL (3 mL, 10 mL) [contains metacresol, phenol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trurapi: 100 units/mL (10 mL) [contains metacresol, phenol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Cartridge, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fiasp: 100 units/mL (3 mL) [contains metacresol, phenol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trurapi: 100 units/mL (3 mL) [contains metacresol, phenol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Pen-injector, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fiasp: 100 units/mL (3 mL) [contains metacresol, phenol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Kirsty: 100 units/mL (3 mL) [contains metacresol, phenol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trurapi Solostar: 100 units/mL (3 mL) [contains metacresol, phenol]</p></div>
<div class="block adm drugH1Div" id="F2104866"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Use only if solution is clear and colorless; do not use if solution contains particulate matter or is colored.</p>
<p style="text-indent:-2em;margin-left:2em;">SUBQ administration: Cold injections should be avoided. SUBQ administration is usually made into the thighs, upper arms, or abdomen; NovoLOG may also be administered in the buttocks. Rotate injection sites within the same region to avoid lipodystrophy or localized cutaneous amyloidosis. Rotating from an injection site where lipodystrophy/cutaneous amyloidosis is present to an unaffected site may increase risk of hypoglycemia. For prefilled pen injectors, prime the needle before each injection with 2 units of insulin. Once injected, hold the needle in the skin for at least 6 seconds after the dose dial has returned to 0 units before the needle is removed to ensure the full dose has been administered.</p>
<p style="text-indent:-2em;margin-left:4em;">Fiasp: Inject at the beginning of or within 20 minutes after starting a meal. Do not mix with any other insulin products or solutions. Fiasp FlexTouch is designed to dial doses in 1-unit increments.</p>
<p style="text-indent:-2em;margin-left:4em;">NovoLOG: Administer within 5 to 10 minutes before a meal. NovoLOG from a vial may be mixed with insulin NPH only (do not mix with other types of insulin) but should be drawn into syringe first. Do not dilute or mix other insulin formulations with NovoLOG contained in a cartridge or prefilled pen. NovoLOG FlexPen and FlexTouch are designed to dial doses in 1-unit increments.</p>
<p style="text-indent:-2em;margin-left:2em;">Continuous SUBQ insulin infusion administration: Patients should be trained in the proper use of their external insulin pump and in intensive insulin therapy; use only in accordance with the infusion pump user manual. Rotate infusion sites within the same region to avoid lipodystrophy or localized cutaneous amyloidosis. Insulin in reservoir should be changed at least every 6 days or replace the PumpCart cartridge at least every 4 days (Fiasp), 7 days (Novolog), or according to continuous SUBQ insulin infusion device user manual (whichever is shorter). Do not dilute or mix other insulin formulations with insulin aspart that is to be used in an external insulin pump.</p>
<p style="text-indent:-2em;margin-left:2em;">IV administration: May be administered IV with close monitoring of blood glucose and serum potassium; appropriate medical supervision is required. <b>Do not administer insulin mixtures intravenously.</b></p>
<p style="text-indent:-2em;margin-left:4em;">IV infusions: To minimize insulin adsorption to plastic IV tubing: Although data is lacking regarding adsorption with insulin aspart, insulin regular loss has been shown to occur by adsorption to plastic (ie, polyvinyl chloride, polyethylene, polyolefin, polypropylene) IV containers and tubing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Greenwood.1','lexi-content-ref-406784','lexi-content-ref-7020415','lexi-content-ref-24143117','lexi-content-ref-22746979']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Greenwood.1','lexi-content-ref-406784','lexi-content-ref-7020415','lexi-content-ref-24143117','lexi-content-ref-22746979'])">Ref</a></span>). Therefore, flush the IV tubing with a priming infusion of 20 mL from the insulin infusion, whenever a new IV tubing set is added to the insulin infusion container (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23164767','lexi-content-ref-22746979']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23164767','lexi-content-ref-22746979'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Also refer to institution-specific protocols where appropriate.</p>
<p style="text-indent:-2em;margin-left:4em;">Because of insulin adsorption to plastic IV tubing or infusion bags, the actual amount of insulin being administered via IV infusion could be substantially less than the apparent amount. Therefore, adjustment of the IV infusion rate should be based on effect and not solely on the apparent insulin dose. The apparent dose may be used as a starting point for determining the subsequent SUBQ dosing regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19454396']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19454396'])">Ref</a></span>); however, the transition to SUBQ administration requires continuous medical supervision, frequent monitoring of blood glucose, and careful adjustment of therapy. In addition, SUBQ insulin should be given 1 to 4 hours prior to the discontinuation of IV insulin to prevent hyperglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19454396']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19454396'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52614088"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Fiasp and NovoLog products are not interchangeable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ISMP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ISMP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Do not use if solution is viscous or cloudy; use only if clear and colorless with no visible particles.</p>
<p style="text-indent:-2em;margin-left:4em;">SUBQ: Avoid cold injections. Administer into the subcutaneous fat of the thighs, arms, or abdomen; NovoLog may also be administered in the buttocks. Rotate injection sites within the same region to reduce the risk of lipodystrophy or localized cutaneous amyloidosis. Rotating from an injection site where lipodystrophy/cutaneous amyloidosis is present to an unaffected site may increase risk of hypoglycemia. For prefilled pen injectors, prime the needle before each injection with 2 units of insulin (use a new needle for each injection); see manufacturer's labeling for specific procedure. Once primed, set dial to the appropriate dose, insert needle into clean skin, and activate device by holding the button down; continue to hold the button until the dose dial has returned to 0 units. After the insulin is injected, hold the needle in the skin for ≥6 seconds after the dose dial has returned to 0 units to ensure the full dose has been administered. Do not rub the area.</p>
<p style="text-indent:-2em;margin-left:6em;">Fiasp: Inject at the beginning of or within 20 minutes after starting a meal. Do not mix with any other insulin products or solutions. Fiasp FlexTouch is designed to dial doses in 1-unit increments.</p>
<p style="text-indent:-2em;margin-left:6em;">NovoLog: Administer immediately (within 5 to 10 minutes) before meals. NovoLog from a vial may be mixed in the same syringe with NPH insulin; do not mix with other types of insulin. When mixing NovoLog with NPH insulin, NovoLog should be drawn into the syringe first. Do not dilute or mix other insulin formulations with NovoLog contained in a cartridge or prefilled pen. NovoLog FlexPen and FlexTouch are designed to dial doses in 1-unit increments.</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous SUBQ insulin infusion (insulin pump): Do not use if solution is viscous or cloudy; use only if clear and colorless. Patients should be trained in the proper use of their external insulin pump and in intensive insulin therapy. Infusion sets and infusion set insertion sites should be changed at least every 3 days; rotate infusion sites. Insulin in reservoir should be changed at least every 6 days or according to continuous subcutaneous insulin infusion device use manual (whichever is shorter). Do not dilute or mix other insulin formulations with insulin aspart that is to be used in an external insulin pump.</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Insulin aspart may be administered IV in selected clinical situations to control hyperglycemia. Closely monitor blood glucose and serum potassium; appropriate medical supervision is required. Do not administer insulin mixtures intravenously.</p>
<p style="text-indent:-2em;margin-left:6em;">To minimize insulin adsorption to IV tubing: Flush the IV tubing with a priming infusion of 20 mL from the insulin infusion, whenever a new IV tubing set is added to the insulin infusion container (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23164767','lexi-content-ref-22746979']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23164767','lexi-content-ref-22746979'])">Ref</a></span>). Also refer to institution-specific protocols where appropriate.</p>
<p style="text-indent:-2em;margin-left:6em;">Because of insulin adsorption to IV tubing or infusion bags, the actual amount of insulin being administered via IV infusion could be substantially less than the apparent amount. Therefore, adjustment of the IV infusion rate should be based on effect and not solely on the apparent insulin dose. The apparent dose may be used as a starting point for determining the subsequent SUBQ dosing regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19454396']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19454396'])">Ref</a></span>); however, the transition to SUBQ administration requires continuous medical supervision, frequent monitoring of blood glucose, and careful adjustment of therapy. In addition, SUBQ insulin should be given 1 to 4 hours prior to the discontinuation of IV insulin to prevent hyperglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19454396']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19454396'])">Ref</a></span>).</p></div>
<div class="block use drugH1Div" id="F2104830"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, types 1 and 2, treatment: </b>Treatment of type 1 diabetes mellitus and type 2 diabetes mellitus to improve glycemic control.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> In Canada, Kirsty and Trurapi are approved as biosimilars to NovoRapid.</p></div>
<div class="block off-label drugH1Div" id="F25474641"><span class="drugH1">Use: Off-Label: Adult</span><p>Diabetic ketoacidosis, mild to moderate, uncomplicated; Gestational diabetes mellitus; Hyperglycemia, hospitalized patients</p></div>
<div class="block mst drugH1Div" id="F2105009"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">NovoLOG may be confused with HumaLOG, HumuLIN R, Nimbex, NovoLIN N, NovoLIN R, NovoLOG Mix 70/30</p>
<p style="text-indent:2em;">NovoLOG Flexpen may be confused with NovoLOG Mix 70/30 Flexpen</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error. <b>
<i>Due to the number of insulin preparations, it is essential to identify/clarify the type of insulin to be used.</i></b></p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Insulin (short- or rapid-acting insulin products used for sliding scale), is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to higher risk of hypoglycemia associated with sliding scale insulin without improvements in hyperglycemia, regardless of care setting. Avoid insulin regimens that only use short- or rapid-acting insulins dosed based on current blood glucose levels in the absence of basal or long-acting insulin; recommendation does not apply to regimens containing basal or long-acting insulin (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Cross-contamination may occur if insulin pens are shared among multiple patients. Steps should be taken to prohibit sharing of insulin pens.</p>
<p style="text-indent:-2em;margin-left:4em;">NovoLOG and Fiasp are not interchangeable; onset of action and timing of administration with respect to meals varies between products.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F8101785"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F2104847"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Glucosidase Inhibitors: May enhance the hypoglycemic effect of Insulins. Management: Consider a decrease in insulin dose when initiating therapy with an alpha-glucosidase inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Beta1 Selective): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Nonselective): May enhance the hypoglycemic effect of Insulins. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Insulins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: May enhance the therapeutic effect of Antidiabetic Agents. Bortezomib may diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: May enhance the hypoglycemic effect of Insulins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipeptidyl Peptidase-IV Inhibitors: May enhance the hypoglycemic effect of Insulins. Management: Consider a decrease in insulin dose when initiating therapy with a dipeptidyl peptidase-IV inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Direct Acting Antiviral Agents (HCV): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edetate CALCIUM Disodium: May enhance the hypoglycemic effect of Insulins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etilefrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon-Like Peptide-1 Agonists: May enhance the hypoglycemic effect of Insulins. Management: Consider insulin dose reductions when used in combination with glucagon-like peptide-1 agonists. Monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Glucose Lowering Effects: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Liraglutide: May enhance the hypoglycemic effect of Insulins. Management: Consider reducing the liraglutide dose if coadministered with insulin. Prescribing information for the Saxenda brand of liraglutide recommends a dose decrease of 50%. Monitor blood glucose for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macimorelin: Insulins may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maitake: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metreleptin: May enhance the hypoglycemic effect of Insulins. Management: Insulin dosage adjustments (including potentially large decreases) may be required to minimize the risk for hypoglycemia with concurrent use of metreleptin.  Monitor closely for signs and symptoms of hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvisomant: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pioglitazone: May enhance the adverse/toxic effect of Insulins. Specifically, the risk for hypoglycemia, fluid retention, and heart failure may be increased with this combination. Management: If insulin is combined with pioglitazone, consider insulin dose reductions to avoid hypoglycemia. Monitor patients for fluid retention and signs/symptoms of heart failure, and consider pioglitazone dose reduction or discontinuation if heart failure occurs<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the hypoglycemic effect of Insulins. Management: Upon initiation of pramlintide, decrease mealtime insulin dose by 50% to reduce the risk of hypoglycemia. Monitor blood glucose frequently and individualize further insulin dose adjustments based on glycemic control.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prothionamide: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rosiglitazone: Insulins may enhance the adverse/toxic effect of Rosiglitazone. Specifically, the risk of fluid retention, heart failure, and hypoglycemia may be increased with this combination. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: May enhance the hypoglycemic effect of Insulins. Management: Consider a decrease in insulin dose when initiating therapy with a sodium-glucose cotransporter 2 inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53273197"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Patients with diabetes mellitus who wish to conceive should use adequate contraception until glycemic control is achieved (ADA 2023). Rapid acting insulin aspart is one of the preferred insulins for use in patients with diabetes mellitus planning to become pregnant (Blumer 2013).</p></div>
<div class="block pri drugH1Div" id="F2104832"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Rapid-acting insulin aspart (NovoLOG) can be detected in cord blood (Pettitt 2007).</p>
<p style="text-indent:0em;margin-top:2em;">Poorly controlled diabetes during pregnancy can be associated with an increased risk of adverse maternal and fetal outcomes, including diabetic ketoacidosis, preeclampsia, spontaneous abortion, preterm delivery, delivery complications, major malformations, stillbirth, and macrosomia. To prevent adverse outcomes, prior to conception and throughout pregnancy, maternal blood glucose and HbA<sub>1c</sub> should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2023; Blumer 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, insulin requirements tend to increase as pregnancy progresses, requiring frequent monitoring and dosage adjustments. Following delivery, insulin requirements decrease rapidly (ACOG 201 2018; ADA 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Insulin is the preferred treatment of type 1 and type 2 diabetes mellitus in pregnancy, as well as gestational diabetes mellitus when pharmacologic therapy is needed (ACOG 190 2018; ACOG 201 2018; ADA 2023). Rapid-acting insulin aspart is one of the preferred insulins for use in pregnancy (ACOG 190 2018; ACOG 201 2018; Blumer 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Maternal use of faster-acting insulin aspart (Fiasp) compared to rapid-acting insulin aspart (NovoLog) in pregnancy is under study (NCT03770767).</p></div>
<div class="block brc drugH1Div" id="F2104834"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">In a study using rapid-acting insulin aspart (NovoRapid), both exogenous and endogenous insulin were present in breast milk (Whitmore 2012). Insulin is not systemically absorbed via breast milk but may provide local benefits to the infant GI tract (Anderson 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">Appropriate glycemic control is required for the establishment of lactation in patients with diabetes mellitus (Anderson 2018). Breastfeeding provides metabolic benefits to mothers with type 1, type 2, and gestational diabetes mellitus as well as their infants; therefore, breastfeeding is encouraged (ACOG 201 2018; ADA 2023; Blumer 2013). Breastfeeding also influences maternal glucose tolerance; close monitoring of patients treated with insulin is recommended as dose adjustments may be required (ADA 2023; Anderson 2018). A small snack before breastfeeding may help decrease the risk of hypoglycemia in patients with pregestational diabetes (ACOG 201 2018; Reader 2004). According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block dic drugH1Div" id="F2104865"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy.</p></div>
<div class="block mop drugH1Div" id="F2104868"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Diabetes mellitus: Blood glucose (individualize frequency based on treatment regimen, hypoglycemia risk, and other patient-specific factors) (ADA 2023); electrolytes; renal function; hepatic function; weight.</p>
<p style="text-indent:-2em;margin-left:4em;">Gestational diabetes mellitus: Blood glucose 4 times daily (1 fasting and 3 postprandial) until glycemic targets are met, then as appropriate (ACOG 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">Hospitalized patients: In patients who are eating, monitor blood glucose before meals and at bedtime; in patients who are not eating or are receiving continuous enteral feeds, monitor blood glucose every 4 to 6 hours (ADA 2023; ES [Umpierrez 2012]). More frequent monitoring may be required in some cases (eg, recurrent hypoglycemia, changes in nutrition, medication changes affecting glycemic control) (ES [Umpierrez 2012]).</p>
<p style="text-indent:-2em;margin-left:6em;">Critically ill patients receiving an IV insulin infusion: Monitor blood glucose every 1 to 2 hours; serum potassium (ADA 2023; SCCM [Jacobi 2012]; manufacturer’s labeling). <b>Note:</b> Arterial or venous whole blood sampling is recommended for patients in shock, on vasopressor therapy, or with severe edema, and when on a prolonged IV insulin infusion (SCCM [Jacobi 2012]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>HbA<sub>1c</sub></i>: Monitor at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; monitor quarterly in patients in whom treatment goals have not been met, or with therapy change. <b>Note: </b>In patients prone to glycemic variability (eg, patients with insulin deficiency) or in patients whose HbA<sub>1c</sub> is discordant with serum glucose levels or symptoms, consider evaluating HbA<sub>1c</sub> in combination with blood glucose levels and/or a glucose management indicator (ADA 2023; KDIGO 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">Diabetic ketoacidosis: Frequent monitoring (eg, every 1 to 4 hours) of serum electrolytes (eg, sodium, potassium, bicarbonate, phosphate), serum glucose, anion gap, venous pH, serum BUN, serum creatinine, serum osmolality, fluid status (eg, BP, fluid intake/output, signs/symptoms of dehydration or fluid overload), anion gap, and mental status. Refer also to institutional protocols (Hirsch 2021; Kitabchi 2009).</p></div>
<div class="block rer drugH1Div" id="F2104855"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Recommendations for glycemic control in patients with diabetes and/or hyperglycemia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nonpregnant adults (AACE [Samson 2023], ADA 2023):</i></p>
<p style="text-indent:-2em;margin-left:6em;">HbA<sub>1c</sub>: &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] HbA<sub>1c</sub> goal may be targeted based on patient-specific characteristics). <b>Note</b>
<b>: </b>In patients using a continuous glucose monitoring system, a goal of time in range &gt;70% with time below range &lt;4% is recommended and is similar to a goal HbA<sub>1c</sub> &lt;7%.</p>
<p style="text-indent:-2em;margin-left:6em;">Preprandial capillary blood glucose: 80 to 130 mg/dL (SI: 4.4 to 7.2 mmol/L) (more or less stringent goals may be appropriate based on patient-specific characteristics).</p>
<p style="text-indent:-2em;margin-left:6em;">Peak postprandial capillary blood glucose (~1 to 2 hours after a meal): &lt;180 mg/dL (SI: &lt;10 mmol/L) (more or less stringent goals may be appropriate based on patient-specific characteristics).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Older adults (≥65 years of age) (ADA 2023):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Consider less strict targets in patients who are using insulin and/or insulin secretagogues (sulfonylureas, meglitinides) (ES [LeRoith 2019]).</p>
<p style="text-indent:-2em;margin-left:6em;">HbA<sub>1c</sub>: &lt;7% to 7.5% (healthy); &lt;8% (complex/intermediate health). <b>Note: </b>Individualization may be appropriate based on patient and caregiver preferences and/or presence of cognitive impairment. In patients with very complex or poor health (ie, limited remaining life expectancy), consider making therapy decisions based on avoidance of hypoglycemia and symptomatic hyperglycemia rather than HbA<sub>1c</sub> level.</p>
<p style="text-indent:-2em;margin-left:6em;">Preprandial capillary blood glucose: 80 to 130 mg/dL (SI: 4.4 to 7.2 mmol/L) (healthy); 90 to 150 mg/dL (SI: 5 to 8.3 mmol/L) (complex/intermediate health); 100 to 180 mg/dL (SI: 5.6 to 10 mmol/L) (very complex/poor health).</p>
<p style="text-indent:-2em;margin-left:6em;">Bedtime capillary blood glucose: 80 to 180 mg/dL (SI: 4.4 to 10 mmol/L) (healthy); 100 to 180 mg/dL (SI: 5.6 to 10 mmol/L) (complex/intermediate health); 110 to 200 mg/dL (SI: 6.1 to 11.1 mmol/L) (very complex/poor health).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pregnant patients:</i></p>
<p style="text-indent:-2em;margin-left:6em;">HbA<sub>1c</sub>: Pregestational diabetes (type 1 or type 2) (ADA 2023):</p>
<p style="text-indent:-2em;margin-left:8em;">Preconception (patients planning for pregnancy): &lt;6.5%.</p>
<p style="text-indent:-2em;margin-left:8em;">During pregnancy &lt;6% (if can be achieved without significant hypoglycemia) or &lt;7% if needed to prevent hypoglycemia.</p>
<p style="text-indent:-2em;margin-left:6em;">Capillary blood glucose: <b>Note: </b>Less stringent targets may be appropriate if goals cannot be achieved without causing significant hypoglycemia (ADA 2023).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Gestational diabetes mellitus (ACOG 2018; ADA 2023):</i></p>
<p style="text-indent:-2em;margin-left:10em;">Fasting: &lt;95 mg/dL (SI: &lt;5.3 mmol/L).</p>
<p style="text-indent:-2em;margin-left:10em;">Postprandial: &lt;140 mg/dL (SI: &lt;7.8 mmol/L) (at 1 hour) or &lt;120 mg/dL (SI: &lt;6.7 mmol/L) (at 2 hours).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Pregestational diabetes mellitus (type 1 or type 2) (ADA 2023</i>
<i>):</i></p>
<p style="text-indent:-2em;margin-left:10em;">Fasting: 70 to 95 mg/dL (SI: 3.9 to 5.3 mmol/L).</p>
<p style="text-indent:-2em;margin-left:10em;">Postprandial: 110 to 140 mg/dL (SI: 6.1 to 7.8 mmol/L) (at 1 hour) <b>or </b>100 to 120 mg/dL (SI: 5.6 to 6.7 mmol/L) (at 2 hours).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hospitalized adult patients (ADA 2023):</i> Target glucose range: 140 to 180 mg/dL (SI: 7.8 to 10 mmol/L) (majority of critically ill and noncritically ill patients; &lt;140 mg/dL [SI: &lt;7.8 mmol/L] may be appropriate for selected patients, if it can be achieved without excessive hypoglycemia).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Perioperative care in adult patients (ADA 2023)</i>: Target glucose range during perioperative period: Consider targeting 80 to 180 mg/dL (SI: 4.4 to 10 mmol/L).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Children and adolescents:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Preprandial glucose: 70 to 130 mg/dL (SI: 3.9 to 7.2 mmol/L) (ISPAD [Dimeglio 2018]).</p>
<p style="text-indent:-2em;margin-left:6em;">Postprandial glucose: 90 to 180 mg/dL (SI: 5 to 10 mmol/L) (ISPAD [Dimeglio 2018]).</p>
<p style="text-indent:-2em;margin-left:6em;">Bedtime/overnight glucose: 80 to 140 mg/dL (SI: 4.4 to 7.8 mmol/L) (ISPAD [Dimeglio 2018]).</p>
<p style="text-indent:-2em;margin-left:6em;">HbA<sub>1c</sub>: &lt;7%; target should be individualized; a more stringent goal (&lt;6.5%) may be reasonable if it can be achieved without significant hypoglycemia; less aggressive goals (&lt;7.5% or &lt;8%) may be appropriate in patients who cannot articulate symptoms of hypoglycemia, cannot check glucose frequently, have a history of severe hypoglycemia, or have extensive comorbid conditions (ADA 2023; ISPAD [Dimeglio 2018]).</p>
<p style="text-indent:-2em;margin-left:6em;">Surgical patients (ISPAD [Jefferies 2018]):</p>
<p style="text-indent:-4em;margin-left:10em;">Intraoperative: 90 to 180 mg/dL (SI: 5 to 10 mmol/L).</p>
<p style="text-indent:-4em;margin-left:10em;">ICU, postsurgery: 140 to 180 mg/dL (SI: 7.8 to 10 mmol/L).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Classification of hypoglycemia (ADA 2023):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Level 1: 54 to 70 mg/dL (SI: 3 to 3.9 mmol/L); hypoglycemia alert value; initiate fast-acting carbohydrate (eg, glucose) treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Level 2: &lt;54 mg/dL (SI: &lt;3 mmol/L); threshold for neuroglycopenic symptoms; requires immediate action.</p>
<p style="text-indent:-2em;margin-left:4em;">Level 3: Hypoglycemia associated with a severe event characterized by altered mental and/or physical status requiring assistance.</p></div>
<div class="block pha drugH1Div" id="F2104853"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Insulin acts via specific membrane-bound receptors on target tissues to regulate metabolism of carbohydrate, protein, and fats. Target organs for insulin include the liver, skeletal muscle, and adipose tissue.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">Within the liver, insulin stimulates hepatic glycogen synthesis. Insulin promotes hepatic synthesis of fatty acids, which are released into the circulation as lipoproteins. Skeletal muscle effects of insulin include increased protein synthesis and increased glycogen synthesis. Insulin stimulates lipoprotein lipase synthesis and activity; this results in hydrolysis of triglycerides into free fatty acids and storage of free fatty acids in adipocytes, thereby reducing circulating triglyceride levels (Rawla 2018; Sadur 1982; Song 2019). In addition, insulin stimulates the cellular uptake of amino acids and increases cellular permeability to several ions, including potassium, magnesium, and phosphate. By activating sodium-potassium ATPases, insulin promotes the intracellular movement of potassium.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">Normally secreted by the pancreas, insulin products are manufactured for pharmacologic use through recombinant DNA technology using either <i>E. coli</i> or <i>Saccharomyces cerevisiae.</i> Insulin aspart differs from human insulin by containing aspartic acid at position B28 in comparison to the proline found in human insulin. Insulins are categorized based on the onset, peak, and duration of effect (eg, rapid-, short-, intermediate-, and long-acting insulin). Insulin aspart is a rapid-acting insulin analog.</p></div>
<div class="block phk drugH1Div" id="F2104856"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Onset and duration of hypoglycemic effects depend upon the route of administration, site of injection (onset and duration are progressively slower with SUBQ injection into the abdomen, arm, buttock, or thigh respectively), volume and concentration of injection, and the preparation administered. Rate of absorption, onset, and duration of activity may be affected by exercise, presence of lipodystrophy, local blood supply, and/or temperature. Insulin aspart is available in a conventional formulation (eg, NovoLOG, NovoRapid [Canadian product]) and a faster-acting formulation (Fiasp) which have slightly different pharmacodynamic/kinetic profiles.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Onset of action: SUBQ:</p>
<p style="text-indent:-2em;margin-left:4em;">Fiasp: 16.1 minutes in patients with type 1 diabetes (~5 minutes earlier than conventional insulin aspart) (Heise 2017); 22.4 ± 1.5 minutes in patients with type 2 diabetes (~9 minutes earlier than conventional insulin aspart) (Pieber 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">NovoLOG: ~0.2 to 0.3 hours (estimated from data in manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Peak effect: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Fiasp: ~1.5 to 2.2 hours in patients with type 1 diabetes (Heise 2017; manufacturer's labeling); peak occurred (~10 minutes earlier than conventional insulin aspart) (Heise 2017); ~2.5 ± 0.15 hours in patients with type 2 diabetes (~5 minutes earlier than conventional insulin aspart) (Pieber 2019).</p>
<p style="text-indent:-2em;margin-left:6em;">NovoLOG: 1 to 3 hours in patients with type 1 diabetes (manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: SUBQ:</p>
<p style="text-indent:-2em;margin-left:4em;">Fiasp: ~5 to 7 hours in patients with type 1 diabetes (dose dependent) (manufacturer's labeling); the offset of glucose lowering effect (time to decrease to 50% of maximum effect) occurred ~14 minutes earlier with Fiasp compared to conventional insulin aspart (Heise 2017; Pieber 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">NovoLOG: 3 to 7.2 hours in patients with type 1 diabetes (Kapitza 2020; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &lt;10%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: SUBQ: Fiasp: 1.1 hours; NovoLOG: 81 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: SUBQ:</p>
<p style="text-indent:-2em;margin-left:4em;">Fiasp: ~63 minutes in patients with type 1 diabetes (Heise 2017; manufacturer's labeling); peak occurred ~7 minutes earlier than conventional insulin aspart (Heise 2017); 70 ± 5.4 minutes in patients with type 2 diabetes (~17 minutes earlier than conventional insulin aspart) (Pieber 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">NovoLOG: 40 to 50 minutes (manufacturer's labeling).</p></div>
<div class="block phksp drugH1Div" id="F51159879"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Obesity: NovoLOG clearance is reduced 28% in patients with a BMI &gt;32 kg/m<sup>2</sup> compared with patients with a BMI &lt;23 kg/m<sup>2</sup>.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F2869465"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Novorapid</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Novorapid</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Novorapid</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Novorapid</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Acilog biopen | Fiasp | Mypart penset | Novorapid</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Novorapid</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Novorapid</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Novorapid</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Insulin novorapid | Novorapid</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Novorapid</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Novorapid</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Novorapid</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Novorapid</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Novorapid</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Fiasp pumpcart | Insulin aspart sanofi | Novorapid</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Novorapid</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Novorapid</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Novorapid</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Novorapid</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Novorapid</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Fiasp</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Insulin aspart sanofi | Novorapid</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Fiasp flextouch | Fiasp penfill | Fiasp pumpcart | Insuline Aspartate | Insuline asparte sanofi | Novorapid | Novorapid pumpcart</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Fiasp flextouch | Fiasp penfill | Novorapid | Trurapi</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Novorapid</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Novorapid</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Novorapid</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Novorapid</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Novorapid | Sansulin rapid</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Kirsty | Kixelle | Novorapid</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Novorapid</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Novorapid</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Insulina aspart sanofi | Novorapid</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Novorapid</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Novorapid</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Novorapid</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Fiasp flextouch | Novorapid</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Novorapid</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Novorapid</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Novorapid</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Fiasp penfill | Fiasp pumpcart | Novorapid</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Insulin aspart sanofi | Novorapid</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Novorapid</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Novorapid</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Novorapid</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Insuline aspart sanofi | Novorapid</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Fiasp pumpcart | Insulin aspart sanofi | Kirsty | Novorapid | Novorapid flexpen | Novorapid flextouch | Novorapid innolet | Novorapid penfill | Novorapid pumpcart</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Insulin novorapid | Novorapid</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Novorapid</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Novorapid</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Novorapid</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Novorapid</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Fiasp flextouch | Fiasp penfill | Novolog</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Novorapid</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Novorapid</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Fiasp Flextouch | Fiasp Penfill | NovoRapid Flexpen | NovoRapid Flextouch | NovoRapid Penfill</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Novorapid</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Novorapid | Rinfast</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Novorapid</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Fiasp pumpcart | Insulin aspart sanofi | Novorapid | Novorapid pumpcart</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Novorapid</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Novorapid</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Novorapid</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Novorapid</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Novorapid</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Novorapid</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Novolog | Novorapid</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Novorapid</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Novorapid</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Novorapid</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Novorapid</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Fiasp | Kixelle | Novorapid</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Novorapid</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29370047">
<a name="29370047"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. <i>Obstet Gynecol</i>. 2018;131(2):e49-e64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/29370047/pubmed" id="29370047" target="_blank">29370047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30461693">
<a name="30461693"></a>American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 201: pregestational diabetes mellitus. <i>Obstet Gynecol</i>. 2018;132(6):e228-e248. doi: 10.1097/AOG.0000000000002960.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/30461693/pubmed" id="30461693" target="_blank">30461693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.2023">
<a name="ADA.2023"></a>American Diabetes Association (ADA). Standards of care in diabetes–2023.<i> Diabetes Care.</i> 2023;45(suppl 1):S1-S291. https://diabetesjournals.org/care/issue/46/Supplement_1. Accessed February 6, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.2020">
<a name="ADA.2020"></a>American Diabetes Association (ADA). Standards of medical care in diabetes–2020. <i>Diabetes Care</i>. 2020;43(suppl 1):S1-S212. https://care.diabetesjournals.org/content/43/Supplement_1. Accessed January 22, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.2021">
<a name="ADA.2021"></a>American Diabetes Association (ADA). Standards of medical care in diabetes–2022.<i> Diabetes Care.</i> 2022;45(suppl 1):S1-S255. https://diabetesjournals.org/care/issue/45/Supplement_1. Accessed September 19, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29608329">
<a name="29608329"></a>Anderson PO. Treating diabetes during breastfeeding. <i>Breastfeed Med</i>. 2018;13(4):237-239. doi:10.1089/bfm.2018.0036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/29608329/pubmed" id="29608329" target="_blank">29608329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25590212">
<a name="25590212"></a>Apovian CM, Aronne LJ, Bessesen DH, et al; Endocrine Society. Pharmacological management of obesity: an Endocrine Society clinical practice guideline [published correction appears in <i>J Clin Endocrinol Metab</i>. 2015;100(5):2135-2136]. <i>J Clin Endocrinol Metab</i>. 2015;100(2):342-362. doi: 10.1210/jc.2014-3415.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/25590212/pubmed" id="25590212" target="_blank">25590212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26472948">
<a name="26472948"></a>Beck JK, Cogen FR. Outpatient management of pediatric type 1 diabetes. <i>J Pediatr Pharmacol Ther</i>. 2015;20(5):344-357.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/26472948/pubmed" id="26472948" target="_blank">26472948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24194617">
<a name="24194617"></a>Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2013;98(11):4227-4249.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/24194617/pubmed" id="24194617" target="_blank">24194617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22111719">
<a name="22111719"></a>Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. <i>N Engl J Med</i>. 2011;365(21):2002-2012.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/22111719/pubmed" id="22111719" target="_blank">22111719</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28183452">
<a name="28183452"></a>Cardoso L, Vicente N, Rodrigues D, Gomes L, Carrilho F. Controversies in the management of hyperglycaemic emergencies in adults with diabetes. <i>Metabolism</i>. 2017;68:43-54. doi:10.1016/j.metabol.2016.11.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/28183452/pubmed" id="28183452" target="_blank">28183452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC). CDC clinical reminder: insulin pens must never be used for more than one person. Centers for Disease Control and Prevention Web site. <a href="https://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html" target="_blank">http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html</a>. Updated January 5, 2012. Accessed January 9, 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935775">
<a name="24935775"></a>Chiang JL, Kirkman MS, Laffel LM, et al; Type 1 Diabetes Sourcebook Authors. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. <i>Diabetes Care</i>. 2014;37(7):2034-54. doi: 10.2337/dc14-1140.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/24935775/pubmed" id="24935775" target="_blank">24935775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14747243">
<a name="14747243"></a>Clement S, Braithwaite SS, Magee MF, et al; American Diabetes Association Diabetes in Hospitals Writing Committee. Management of diabetes and hyperglycemia in hospitals. <i>Diabetes Care</i>. 2004;27(2):553-591. doi:10.2337/diacare.27.2.553<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/14747243/pubmed" id="14747243" target="_blank">14747243</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24829176">
<a name="24829176"></a>Cruijsen M, Koehestani P, Huttjes S, Leenders K, Janssen I, de Boer H. Perioperative glycaemic control in insulin-treated type 2 diabetes patients undergoing gastric bypass surgery. <i>Neth J Med</i>. 2014;72(4):202-209.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/24829176/pubmed" id="24829176" target="_blank">24829176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29999222">
<a name="29999222"></a>Danne T, Phillip M, Buckingham BA, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Insulin treatment in children and adolescents with diabetes. <i>Pediatr Diabetes</i>. 2018;19(suppl 27):115-135. doi: 10.1111/pedi.12718.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/29999222/pubmed" id="29999222" target="_blank">29999222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15920040">
<a name="15920040"></a>Davies M, Storms F, Shutler S, et al, “Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes,” <i>Diabetes Care</i>, 2005, 28(6):1282-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/15920040/pubmed" id="15920040" target="_blank">15920040</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30291106">
<a name="30291106"></a>Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i>. 2018;41(12):2669-2701. doi:10.2337/dci18-0033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/30291106/pubmed" id="30291106" target="_blank">30291106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36537523">
<a name="36537523"></a>de Bock M, Codner E, Craig ME, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Glycemic targets and glucose monitoring for children, adolescents, and young people with diabetes. <i>Pediatr Diabetes</i>. 2022;23(8):1270-1276. doi:10.1111/pedi.13455<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/36537523/pubmed" id="36537523" target="_blank">36537523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30058221">
<a name="30058221"></a>DiMeglio LA, Acerini CL, Codner E, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. <i>Pediatr Diabetes</i>. 2018;19 Suppl 27:105-114.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/30058221/pubmed" id="30058221" target="_blank">30058221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fiasp.2">
<a name="Fiasp.2"></a>Fiasp (insulin aspart) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fiasp.3">
<a name="Fiasp.3"></a>Fiasp (insulin aspart) [product monograph]. Mississauga, Ontario, Canada: Novo Nordisk Canada Inc; February 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FiaspPenFIll.1">
<a name="FiaspPenFIll.1"></a>Fiasp PenFill (insulin aspart) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; October 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32022600">
<a name="32022600"></a>Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. <i>Endocr Pract</i>. 2020;26(1):107-139. doi:10.4158/CS-2019-0472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/32022600/pubmed" id="32022600" target="_blank">32022600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32931166">
<a name="32931166"></a>Gianchandani RY, Iyengar JL, Butler SO, et al. Inpatient diabetes guideline for adult non-critically ill patients. Michigan Medicine, University of Michigan; May 2020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/32931166/pubmed" id="32931166" target="_blank">32931166</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Greenwood.1">
<a name="Greenwood.1"></a>Greenwood BC, Chesnick MA, Szumita PM, Belisle C, Cotugno M. Stability of regular human insulin extemporaneously prepared in 0.9% sodium chloride in a polyvinyl chloride bag. <i>Hosp Pharm.</i> 2012;47(5):367-370.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25869408">
<a name="25869408"></a>Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. <i>Endocr Pract</i>. 2015;21(suppl 1):1-87. https://journals.aace.com/doi/pdf/10.4158/EP15672.GLSUPPL. Accessed April 22, 2020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/25869408/pubmed" id="25869408" target="_blank">25869408</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28205039">
<a name="28205039"></a>Heise T, Pieber TR, Danne T, Erichsen L, Haahr H. A pooled analysis of clinical pharmacology trials investigating the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in adults with type 1 diabetes. <i>Clin Pharmacokinet</i>. 2017;56(5):551-559. doi:10.1007/s40262-017-0514-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/28205039/pubmed" id="28205039" target="_blank">28205039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hirsch.1">
<a name="Hirsch.1"></a>Hirsch IB, Emmett M. Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed September 27, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-406784">
<a name="406784"></a>Hirsch JI, Fratkin MJ, Wood JH, Thomas RB. Clinical significance of insulin adsorption by polyvinyl chloride infusion systems. <i>Am J Hosp Pharm</i>. 1977;34(6):583-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/406784/pubmed" id="406784" target="_blank">406784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7020415">
<a name="7020415"></a>Hirsch JI, Wood JH, Thomas RB. Insulin adsorption to polyolefin infusion bottles and polyvinyl chloride administration sets. <i>Am J Hosp Pharm</i>. 1981;38(7):995-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/7020415/pubmed" id="7020415" target="_blank">7020415</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.1">
<a name="ISMP.1"></a>Institute for Safe Medication Practices (ISMP). ISMP medication safety alert, acute care https://www.ismp.org/newsletters/acute-care. Updated August 1, 2019. Accessed October 21, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Inzucchi.1">
<a name="Inzucchi.1"></a>Inzucchi SE. Diabetes facts and guidelines. <a href="https://medicine.yale.edu/intmed/drc/diabetescenter/living/50135_Yale%20National%20F_102165_284_13584_v1.pdf" target="_blank">https://medicine.yale.edu/intmed/drc/diabetescenter/living/50135_Yale%20National%20F_102165_284_13584_v1.pdf</a>. Published 2011. Accessed January 13, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25538310">
<a name="25538310"></a>Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i>. 2015;38(1):140-149.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/25538310/pubmed" id="25538310" target="_blank">25538310</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23164767">
<a name="23164767"></a>Jacobi J, Bircher N, Krinsley J, et al. Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients. <i>Crit Care Med.</i> 2012;40(12):3251-3276. doi:10.1097/CCM.0b013e3182653269<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/23164767/pubmed" id="23164767" target="_blank">23164767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30039617">
<a name="30039617"></a>Jefferies C, Rhodes E, Rachmiel M, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Management of children and adolescents with diabetes requiring surgery. <i>Pediatr Diabetes</i>. 2018;19(suppl 27):227-236.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/30039617/pubmed" id="30039617" target="_blank">30039617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36537521">
<a name="36537521"></a>Kapellen T, Agwu JC, Martin L, et al. ISPAD clinical practice consensus guidelines 2022: management of children and adolescents with diabetes requiring surgery. <i>Pediatr Diabetes</i>. 2022;23(8):1468-1477. doi:10.1111/pedi.13446<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/36537521/pubmed" id="36537521" target="_blank">36537521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31825248">
<a name="31825248"></a>Kapitza C, Nosek L, Schmider W, Teichert L, Nowotny I. Single-dose euglycemic clamp study demonstrating pharmacokinetic and pharmacodynamic similarity between SAR341402 insulin aspart and US- and EU-approved versions of insulin aspart in subjects with type 1 diabetes. <i>Diabetes Technol Ther.</i> 2020;22(4):278-284. doi:10.1089/dia.2019.0351<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/31825248/pubmed" id="31825248" target="_blank">31825248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32998798">
<a name="32998798"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. <i>Kidney Int</i>. 2020;98(4S):S1-S115. doi:10.1016/j.kint.2020.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/32998798/pubmed" id="32998798" target="_blank">32998798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23106132">
<a name="23106132"></a>Kirkman M, Briscoe VJ, Clark N, et al, "Diabetes in Older Adults: A Consensus Report," <i>J Am Geriatr Soc</i>, 2012; doi: 10.1111/jgs.12035.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/23106132/pubmed" id="23106132" target="_blank">23106132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kirsty.1">
<a name="Kirsty.1"></a>Kirsty (insulin aspart) [product monograph]. Etobicoke, Ontario, Canada: BGP Pharma ULC; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19564476">
<a name="19564476"></a>Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. <i>Diabetes Care</i>. 2009;32(7):1335-1343. doi:10.2337/dc09-9032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/19564476/pubmed" id="19564476" target="_blank">19564476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14693938">
<a name="14693938"></a>Kitabchi AE, Umpierrez GE, Murphy MB, et al, "Hyperglycemic Crises in Diabetes,” <i>Diabetes Care</i>, 2004, 27(Suppl 1): 94-102.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/14693938/pubmed" id="14693938" target="_blank">14693938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19417773">
<a name="19417773"></a>Korner J, Inabnet W, Febres G, et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. <i>Int J Obes (Lond).</i> 2009;33(7):786-795. doi: 10.1038/ijo.2009.79.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/19417773/pubmed" id="19417773" target="_blank">19417773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30903688">
<a name="30903688"></a>LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2019;104(5):1520-1574. doi:10.1210/jc.2019-00198<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/30903688/pubmed" id="30903688" target="_blank">30903688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29162977">
<a name="29162977"></a>Leung V, Ragbir-Toolsie K. Perioperative management of patients with diabetes. <i>Health Serv Insights</i>. 2017;10:1178632917735075. doi:10.1177/1178632917735075<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/29162977/pubmed" id="29162977" target="_blank">29162977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29162977">
<a name="29162977"></a>Magaji V, Johnston JM. Inpatient management of hyperglycemia and diabetes. <i>Clin Diabetes</i>. 2011;29(1):3-9. doi:10.2337/diaclin.29.1.3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/29162977/pubmed" id="29162977" target="_blank">29162977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29316130">
<a name="29316130"></a>Mathieu C, Bode BW, Franek E, et al. Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial. <i>Diabetes Obes Metab</i>. 2018;20(5):1148-1155. doi: 10.1111/dom.13205.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/29316130/pubmed" id="29316130" target="_blank">29316130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31917200">
<a name="31917200"></a>Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic &amp; Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. <i>Surg Obes Relat Dis</i>. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/31917200/pubmed" id="31917200" target="_blank">31917200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Meneghini.1">
<a name="Meneghini.1"></a>Meneghini L, Koenen C, Rojas P, et al, “Efficacy and Safety of Insulin Detemir in a Large Cohort of Patients With Type 2 Diabetes Using a Simplified Self-Adjusted Dosing Guideline -- Results of the Predictive 303 Study,” Presented at: 67th Scientific Sessions of the American Diabetes Association; June 22-25, 2007; Chicago, Ill.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19454396">
<a name="19454396"></a>Moghissi ES, Korytkowski MT, DiNardo M, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. <i>Endocr Pract.</i> 2009;15(4):353-369.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/19454396/pubmed" id="19454396" target="_blank">19454396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19318384">
<a name="19318384"></a>NICE-SUGAR Study Investigators, Finfer S, Chittock DR, et al, “Intensive Versus Conventional Glucose Control in Critically Ill Patients,” <i>N Engl J Med</i>, 2009, 360(13):1283-97.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/19318384 /pubmed" id="19318384 " target="_blank">19318384 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NovoLog.1">
<a name="NovoLog.1"></a>NovoLog (insulin aspart) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; February 2023.</div>
</li>
<li>
<div class="reference">
                  NovoLog Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; March 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NovoRapid.1">
<a name="NovoRapid.1"></a>NovoRapid (insulin aspart) [product monograph]. Mississauga, Ontario, Canada: Novo Nordisk Canada Inc; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21741089">
<a name="21741089"></a>Oyer DS, Shepherd MD, Coulter FC, et al. Efficacy and tolerability of self-titrated biphasic insulin aspart 70/30 in patients aged &gt;65 years with type 2 diabetes: an exploratory post hoc subanalysis of the INITIATEplus trial. <i>Clin Ther</i>. 2011;33(7):874-883.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/21741089/pubmed" id="21741089" target="_blank">21741089</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22354457">
<a name="22354457"></a>Peterli R, Steinert RE, Woelnerhanssen B, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. <i>Obes Surg</i>. 2012;22(5):740-748. doi: 10.1007/s11695-012-0622-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/22354457/pubmed" id="22354457" target="_blank">22354457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Peters.1">
<a name="Peters.1"></a>Peters AP, Laffel L, eds. <i>Type 1 Diabetes Sourcebook</i>. Alexandria, VA: American Diabetes Association; 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17888133">
<a name="17888133"></a>Pettitt DJ, Ospina P, Howard C, et al. Efficacy, Safety and Lack of Immunogenicity of Insulin Aspart Compared With Regular Human Insulin for Women With Gestational Diabetes Mellitus. <i>Diabet Med.</i> 2007;24(10):1129-1135.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/17888133/pubmed" id="17888133" target="_blank">17888133</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12502678">
<a name="12502678"></a>Pettitt DJ, Ospina P, Kolaczynski JW, Jovanovic L. Comparison of an insulin analog, insulin aspart, and regular human insulin with no insulin in gestational diabetes mellitus. <i>Diabetes Care</i>. 2003;26(1):183-186.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/12502678/pubmed" id="12502678" target="_blank">12502678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31069935">
<a name="31069935"></a>Pieber TR, Svehlikova E, Brunner M, Halberg IB, Due Thomsen KM, Haahr H. Fast-acting insulin aspart in people with type 2 diabetes: earlier onset and greater initial exposure and glucose-lowering effect compared with insulin aspart. <i>Diabetes Obes Metab</i>. 2019;21(9):2068-2075. doi:10.1111/dom.13767<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/31069935/pubmed" id="31069935" target="_blank">31069935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29923163">
<a name="29923163"></a>Rawla P, Sunkara T, Thandra KC, Gaduputi V. Hypertriglyceridemia-induced pancreatitis: updated review of current treatment and preventive strategies. <i>Clin J Gastroenterol</i>. 2018;11(6):441-448. doi:10.1007/s12328-018-0881-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/29923163/pubmed" id="29923163" target="_blank">29923163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28924481">
<a name="28924481"></a>Rawla P, Vellipuram AR, Bandaru SS, Pradeep Raj J. Euglycemic diabetic ketoacidosis: a diagnostic and therapeutic dilemma. <i>Endocrinol Diabetes Metab Case Rep</i>. 2017;2017:17-0081. doi:10.1530/EDM-17-0081<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/28924481/pubmed" id="28924481" target="_blank">28924481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29797212">
<a name="29797212"></a>Razavi Z, Maher S, Fredmal J. Comparison of subcutaneous insulin aspart and intravenous regular insulin for the treatment of mild and moderate diabetic ketoacidosis in pediatric patients. <i>Endocrine</i>. 2018;61(2):267-274.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/29797212/pubmed" id="29797212" target="_blank">29797212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15461903">
<a name="15461903"></a>Reader D, Franz MJ. Lactation, diabetes, and nutrition recommendations. <i>Curr Diab Rep</i>. 2004;4(5):370-376.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/15461903/pubmed" id="15461903" target="_blank">15461903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28101605">
<a name="28101605"></a>Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. <i>Intensive Care Med</i>. 2017;43(3):304-377.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/28101605/pubmed" id="28101605" target="_blank">28101605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14578243">
<a name="14578243"></a>Riddle MC, Rosenstock J, Gerich J, et al. The Treat-to-Target Trial: Randomized Addition of Glargine or Human NPH Insulin to Oral Therapy of Type 2 Diabetic Patients. <i>Diabetes Care. </i>2003;26(11):3080-3086.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/14578243/pubmed" id="14578243" target="_blank">14578243</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24143117">
<a name="24143117"></a>Rocchio MA, Belisle CD, Greenwood BC, Cotugno MC, Szumita PM. Evaluation of the maximum beyond-use-date stability of regular human insulin extemporaneously prepared in 0.9% sodium chloride in a polyvinyl chloride bag. <i>Diabetes Metab Syndr Obes</i>. 2013 Oct 11;6:389-92.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/24143117/pubmed" id="24143117" target="_blank">24143117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7040473">
<a name="7040473"></a>Sadur CN, Eckel RH. Insulin stimulation of adipose tissue lipoprotein lipase. Use of the euglycemic clamp technique. <i>J Clin Invest</i>. 1982;69(5):1119-1125. doi:10.1172/jci110547<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/7040473/pubmed" id="7040473" target="_blank">7040473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37150579">
<a name="37150579"></a>Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm – 2023 update. <i>Endocr Pract</i>. 2023;29(5):305-340. doi:10.1016/j.eprac.2023.02.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/37150579/pubmed" id="37150579" target="_blank">37150579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20550713">
<a name="20550713"></a>Savoldelli RD, Farhat SC, Manna TD. Alternative management of diabetic ketoacidosis in a Brazilian pediatric emergency department. <i>Diabetol Metab Syndr</i>. 2010;2:41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/20550713/pubmed" id="20550713" target="_blank">20550713</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36161685">
<a name="36161685"></a>Shah AS, Zeitler PS, Wong J, et al. ISPAD clinical practice consensus guidelines 2022: type 2 diabetes in children and adolescents. <i>Pediatr Diabetes</i>. 2022;23(7):872-902. doi:10.1111/pedi.13409<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/36161685/pubmed" id="36161685" target="_blank">36161685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15616254">
<a name="15616254"></a>Silverstein J, Klingensmith G, Copeland K, et al. Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. <i>Diabetes Care</i>. 2005;28(1):186-212.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/15616254/pubmed" id="15616254" target="_blank">15616254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31215460">
<a name="31215460"></a>Song X, Shi D, Cui Q, et al. Intensive insulin therapy versus plasmapheresis in the management of hypertriglyceridemia-induced acute pancreatitis (Bi-TPAI trial): study protocol for a randomized controlled trial. <i>Trials</i>. 2019;20(1):365. doi:10.1186/s13063-019-3498-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/31215460/pubmed" id="31215460" target="_blank">31215460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28726299">
<a name="28726299"></a>Sundberg F, Barnard K, Cato A, et al. ISPAD Guidelines. Managing diabetes in preschool children. <i>Pediatr Diabetes</i>. 2017;18(7):499-517. doi: 10.1111/pedi.12554.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/28726299/pubmed" id="28726299" target="_blank">28726299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22746979">
<a name="22746979"></a>Thompson CD, Vital-Carona J, Faustino EV. The effect of tubing dwell time on insulin adsorption during intravenous insulin infusions. <i>Diabetes Technol Ther</i>. 2012;14(10):912-916.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/22746979/pubmed" id="22746979" target="_blank">22746979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Trurapi.1">
<a name="Trurapi.1"></a>Trurapi (insulin aspart) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; July 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15277410">
<a name="15277410"></a>Umpierrez GE, Cuervo R, Karabell A, et al. Treatment of Diabetic Ketoacidosis With Subcutaneous Insulin Aspart. <i>Diabetes Care.</i> 2004;27(8):1873-1878.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/15277410/pubmed" id="15277410" target="_blank">15277410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22223765">
<a name="22223765"></a>Umpierrez GE, Hellman R, Korytkowski MT, et al; Endocrine Society. Management of hyperglycemia in hospitalized patients in non-critical care setting: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2012;97(1):16-38. doi:10.1210/jc.2011-2098<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/22223765/pubmed" id="22223765" target="_blank">22223765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19366972">
<a name="19366972"></a>Umpierrez GE, Jones S, Smiley D, et al. Insulin Analogs Versus Human Insulin in the Treatment of Patients With Diabetic Ketoacidosis: A Randomized Controlled Trial. <i>Diabetes Care.</i> 2009;32(7):1164-1169.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/19366972/pubmed" id="19366972" target="_blank">19366972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.1">
<a name="NIH.1"></a>US National Library of Medicine. Insulin Fiasp vs. insulin NovoRapid during pregnancy and lactation in women with pre-existing diabetes. <i>National Institute of Health. </i>
<a href="https://clinicaltrials.gov/ct2/show/NCT03770767?term=NCT03770767&amp;rank=1" target="_blank">https://clinicaltrials.gov/ct2/show/NCT03770767?term=NCT03770767&amp;rank=1</a>. Updated September 9, 2020. Accessed February 11, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wexler.1">
<a name="Wexler.1"></a>Wexler DJ. Insulin therapy in type 2 diabetes mellitus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed September 19, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22500167">
<a name="22500167"></a>Whitmore TJ, Trengove NJ, Graham DF, Hartmann PE. Analysis of insulin in human breast milk in mothers with type 1 and type 2 diabetes mellitus. <i>Int J Endocrinol</i>. 2012;2012:296368.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/22500167/pubmed" id="22500167" target="_blank">22500167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18728267">
<a name="18728267"></a>Wiener RS, Wiener DC, Larson RJ. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. <i>JAMA</i>. 2008;300(8):933-944.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/18728267/pubmed" id="18728267" target="_blank">18728267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29900641">
<a name="29900641"></a>Wolfsdorf JI, Glaser N, Agus M, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Diabetic ketoacidosis and the hyperglycemic hyperosmolar state. <i>Pediatr Diabetes</i>. 2018;19(Suppl 27):155–177.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/insulin-aspart-including-biosimilars-available-in-canada-drug-information/abstract-text/29900641/pubmed" id="29900641" target="_blank">29900641</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9020 Version 355.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
